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GLP-1 (glucagon-like peptide-1) is an incretin released from
intestinal L-cells in response to food intake. Activation of the
GLP-1 receptor potentiates the synthesis and release of insulin
from pancreatic -cells in a glucose-dependent manner. The
GLP-1 receptor belongs to class B of theG-protein-coupled recep-
tors, a subfamily characterized by a large N-terminal extracellular
ligand binding domain. Exendin-4 and GLP-1 are 50% identical,
and exendin-4 is a full agonist with similar affinity and potency for
theGLP-1 receptor.We recently solved the crystal structure of the
GLP-1 receptor extracellular domain in complexwith the compet-
itive antagonist exendin-4(9–39). Interestingly, the isolated extra-
cellulardomainbindsexendin-4withmuchhigheraffinity thanthe
endogenous agonistGLP-1.Here, we have solved the crystal struc-
ture of the extracellular domain in complex with GLP-1 to 2.1 A˚
resolution. The structure shows that important hydrophobic
ligand-receptor interactions are conserved in agonist- and antago-
nist-bound forms of the extracellular domain, but certain residues
in the ligand-binding site adopt a GLP-1-specific conformation.
GLP-1 isakinkedbutcontinuous-helix fromThr13 toVal33when
bound to the extracellular domain. We supplemented the crystal
structure with site-directed mutagenesis to link the structural
information of the isolated extracellular domain with the bind-
ing properties of the full-length receptor. The data support the
existence of differences in the binding modes of GLP-1 and
exendin-4 on the full-length GLP-1 receptor.
GLP-1 (glucagon-like peptide-1) is a peptide hormone pro-
duced by post-translational processing of proglucagon in the
intestinal L-cells (1). GLP-1 is an incretin that potentiates the
synthesis and release of insulin from pancreatic -cells in a
glucose-dependent manner (2) and has a number of other ben-
eficial effects that contribute to reducing blood sugar (3–6). In
addition, GLP-1 has been shown to reduce bodyweight (3, 5, 7),
which is favorable formany people with type 2 diabetes. Hence,
GLP-1-based therapies are becoming increasingly attractive for
the treatment of type 2 diabetes. The actions of GLP-1 are
mediated through the GLP-1 receptor (GLP-1R),3 which is a
seven-transmembrane G protein-coupled receptor (GPCR)
coupled to adenylyl cyclase (8). The human GLP-1R was first
cloned in 1992 and belongs to class B of GPCRs (9). This class
includes a wide range of receptors for peptide hormones like
glucagon, GLP-2 (glucagon-like peptide-2), glucose-
dependent insulinotropic polypeptide (GIP), pituitary aden-
ylyl cyclase-activating polypeptide (PACAP), vasoactive
intestinal polypeptide, secretin, calcitonin, corticotrophin-
releasing factor, and parathyroid hormone (PTH) (10). The
receptors are distinguished by their large extracellular
N-terminal domain (ECD), which is important for ligand
binding and selectivity (11, 12). The current binding model
suggests a two-domain mechanism where the C-terminal
part of the ligand binds the ECD and the N-terminal part of
the ligand binds the extracellular loops and transmembrane
-helices (TM domain), which leads to receptor activation
(reviewed in Ref. 13).
The first structure of an isolated ECD of a class B GPCR
was solved recently by NMR spectroscopy (14). Subse-
quently, structures of ligand-bound ECDswere solved, includ-
ing the ECD of the human type 1 corticotrophin-releasing fac-
tor receptor 1 (15), the human type 1 PACAP receptor (16), the
human GIP receptor (17), the human GLP-1R (18), and the
human type 1 PTH receptor (19). The ECDs of class B receptors
have a common structure, the secretin recognition fold, which
is stabilized by three conserved disulfide bonds and five con-
served residues (Asp67, Trp72, Pro86, Gly108, andTrp110 inGLP-
1R). The receptor-bound ligands are primarily in-helical con-
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formation, and the C-terminal part of the ligands binds the
ECD in agreement with the two-domain binding mechanism.
Several receptor models have been proposed for full-length
class B receptors (20–23). However, the orientation of the ECD
relative to the TM domain is uncertain.
Exendin-4 is a 39-amino acid peptide, which was originally
isolated from the venom of the lizard Heloderma suspectum
(24). GLP-1 and exendin-4 are 50% identical, and exendin-4 is a
full agonist with similar affinity and potency for the full-length
GLP-1R (25). However, structure-activity studies have demon-
strated interesting differences between the binding modes of
GLP-1 and exendin-4. 1) The isolated ECD binds exendin-4
with high affinity (IC50 of 6 nM) and GLP-1 with low affinity
(IC50500 nM) (26, 27). 2) GLP-1 binding is more sensitive to
site-directed mutagenesis of the TM domain compared with
exendin-4 binding (28–30). 3) GLP-1 ismuchmore sensitive to
N-terminal truncation than exendin-4 (31). N-terminally trun-
cated exendin-4 variants maintain high affinity but are unable
to activate GLP-1R, i.e. competitive antagonist, whereas N-ter-
minal truncation of GLP-1 severely affects both binding and
activation (31). Clearly, the interaction between theN-terminal
part of GLP-1 and the TM domain is critical for binding and
activation of GLP-1R.
Exendin-4(9–39) is a truncated form of exendin-4, and a
competitive antagonist that maintains high affinity for GLP-1R
through interactions with the ECD (IC50 value of 6 nM for the
isolated ECD) (27, 32). We recently solved the crystal structure
of the GLP-1R ECD in complex with exendin-4(9–39) (18).
Exendin-4(9–39) is -helical in the ECD-bound conformation
except for the C-terminal segment, the so-called Trp cage (33,
34). In solution, the helical propensity of exendin-4 is higher
than that of GLP-1 (27, 33). Biophysical studies showed a pos-
itive correlation between -helical propensity in solution and
affinity for the GLP-1R ECD (27). Moreover, charged residues
of exendin-4 interact with the ECD in amanner not possible for
GLP-1 (18). Hence, the high affinity of exendin-4 for the ECD
may be a combination of high helical propensity in solution and
unique receptor interactions.
Here, we report the crystal structure of the GLP-1R ECD in
complex with its endogenous agonist GLP-1. We supple-
mented the crystal structure with site-directed mutagenesis to
link the structural information of the isolated ECD with the
binding properties of the full-length receptor.
EXPERIMENTAL PROCEDURES
Protein and Peptide Preparation—The GLP-1R ECD was
prepared as described previously (27). Briefly, N-terminal His6-
tagged ECD was expressed in Escherichia coli inclusion bodies,
isolated as inclusion body protein, solubilized in guanidine-HCl
and dithiothreitol, dialyzed against guanidine-HCl to remove
the dithiothreitol, and refolded using L-Arg and a 1:5 molar
ratio of reduced and oxidized glutathione. The refolded ECD
was purified by hydrophobic interaction chromatography and
size exclusion chromatography in 10 mM Tris-HCl, pH 7.5, 0.1
M Na2SO4, 2% glycerol. The His6 tag was removed by thrombin
cleavage. The purified GLP-1R ECD consisted of four amino
acids, Gly-Ser-His-Met, of the linker attached to the N-termi-
nus of ECD (Arg24–Tyr145),Mr 14,723 g/mol after removal of
the His6 tag. Native GLP-1(7–37)-OH was synthesized as
described previously (12).
Purification and Crystallization of the GLP-1-bound Extra-
cellularDomain—The purifiedGLP-1R ECDwas concentrated
to 1.2 mg/ml, mixed with 3-fold molar excess of GLP-1(7–37)
(dissolved in 50mMTris-HCl, pH 7.5), and incubated overnight
at 4 °C. The GLP-1-bound ECD was purified by size exclusion
chromatography on a Superdex 75 column in 10 mM Tris-HCl,
pH 7.5, at a flow rate of 0.3 ml/min and characterized by SDS-
PAGE (supplemental Fig. S1). The complex was concentrated
to 4 mg/ml and crystallized by hanging drop vapor diffusion.
The crystallization conditions were initially identified using the
Crystal Screen fromHampton Research and subsequently opti-
mized to 0.1 M N(2-acetamido)iminodiacetic acid, pH 6.9, 14
volume % ()-2-methyl-2,4-pentanediol and 9 mM n-decyl--
D-thiomaltoside. Single crystalswere flashed cooled in liquidN2
using 30% glycerol in the cryo solution.
Data Collection and Structure Determination—Diffraction
data were collected from a single crystal using beamline 1911-3
at MAX-lab (Lund, Sweden). The data were integrated and
scaled using XDS (35). The crystals belonged to space group
P21221with the unit cell dimensions a 35.7Å, b 42.7Å, and
c 95.1 Å. The phases and electron densitymapwere obtained
by molecular replacement using Phaser running in the CCP4
program interface with one complex in the asymmetric unit.
Refinement was done using COOT (36) and REFMAC5 (37).
Well defined electron density was obtained for GLP-1 residues
Thr11*–Val33* and for ECD residues Val30–Glu128. Poor den-
sity was observed for GLP-1 residues Gly10*, Lys34*, and Gly35*
and ECD residues Thr29 and Asn115. No electron density was
observed for His7*–Glu9* and Arg36*–Gly37* of GLP-1. Our
final structure containsGLP-1 residuesGly10*–Gly35* and ECD
residues Thr29–Glu128, but it should be noted that the confor-
mation of Lys34* of GLP-1 is very uncertain, and because of the
poor density we have chosen to show Asn115 as Gly. The final
GLP-1-bound ECD structure has 116 residues in preferred
regions, 5 in allowed regions and only 1 outlier (Glu68 in the
-turn between 1 and 2 shown in Fig. 1A) in the Ramachan-
dran plot. The structure containing 73 water molecules and a
detergent molecule (n-decyl--D-thiomaltoside) has a working
R-factor of 0.181% and a freeR-factor of 0.226%.Data collection
and refinement statistics are summarized in Table 1. Coordi-
nates and structure factors are deposited in the Protein Data
Bank under accession code 3IOL.Molecular graphics were pre-
pared in PyMOL (46).
Receptor Constructs—The cDNA encoding the human GLP-
1R was originally obtained from Dr. B. Thorens (9) and sub-
cloned into the mammalian expression vector pcDNA3.1/
v5-His-TOPO (Invitrogen). The presence of the C-terminal
His6 tag was previously shown not to influence the functional
response of the receptor (12). Site-directed mutagenesis of
GLP-1R was done using QuikChangeTM (Stratagene). Plasmid
DNAwas generated using the NucleoBondXtraMaxi Plus kit
(Macherey-Nagel), and the desired mutations were confirmed
by dideoxynucleotide sequencing.
Cell Culture and Receptor Expression—Human embryonic
kidney (HEK) 293 cellsweremaintained inDulbecco’smodified
Eagle’s medium (BioWhittaker) supplemented with 10 volume
Crystal Structure of Receptor-bound GLP-1
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% fetal bovine serum and 1 volume % penicillin/streptomycin
(100 units/ml) in T175 flasks. HEK293 cells were transiently
transfected with 21 g of GLP-1R DNA using the FuGENETM
transfection reagent (Roche Applied Science), harvested
24 h after transfection, and used directly in functional exper-
iments or plasma membrane preparations as described pre-
viously (12).
Functional Assay—Transiently transfected HEK293 cells
expressing wild-type GLP-1R or mutant receptors were har-
vested and resuspended in assay buffer (Flashplate,
PerkinElmer Life Sciences) to a cell density of 2.4  106 cells/
ml. GLP-1(7–37)-acid and exendin-4 were diluted in phos-
phate-buffered saline with 0.02 volume % Tween 20. Cells in
assay buffer (50l) and GLP-1 or exendin-4 (50l) weremixed
in 96-well FlashPlates (PerkinElmer Life Sciences), gently agi-
tated for 5min, and incubated for 25min at room temperature.
The resulting intracellular level of cAMPwasmeasured accord-
ing to supplier’s manual and analyzed by nonlinear regression/
sigmoidal dose-response fitting using Prism 5.0 (GraphPad
Software, Inc.).
Receptor Binding Assay—Freshly
thawed plasma membrane prepara-
tions from transiently transfected
HEK293 cells expressing GLP-1R
(20 g protein/well) were pulled
through a 25-gauge needle three
times and diluted in assay buffer (50
mM HEPES, 5 mM MgCl2, 5 mM
EGTA, 0.005 volume % Tween 20,
pH 7.4). GLP-1 and exendin-4 were
diluted in assay buffer. The concen-
tration range was 1 pM to 100 nM
for GLP-1 and exendin-4. 125I-GLP-
1(7–36)-amide (2.2 Ci/mol) was
dissolved in assay buffer and added
at 50,000 cpm per well to a final
concentration of 50 pM. Nonspe-
cific binding was determined with
1 M GLP-1. Membrane prepara-
tion and radioligand were mixed in
96-well 0.65-m filter plates (Milli-
pore) with either diluted GLP-1 or
exendin-4 and incubated for 1 h at
37 °C. Subsequently, bound and
unbound radioligands were sepa-
rated by vacuum filtration (Milli-
pore vacuum manifold). The filters
were washed twice in 100 l of cold
assay buffer and left to dry. Data
were analyzed by nonlinear regres-
sion, and the expression level (Bmax)
was calculated using Prism 5.0
(GraphPad Software, Inc.).
RESULTS ANDDISCUSSION
Purification, Crystallization, and
Structure Determination—The GLP-
1R ECD was expressed in E. coli
inclusion bodies, refolded, and purified as described previously
(27). A complex of GLP-1 and the ECD was purified by size
exclusion chromatography (supplemental Fig. S1). The purified
complex was characterized by SDS-PAGE (supplemental Fig.
S1), concentrated, and crystallized by hanging drop vapor dif-
fusion. Diffraction data were collected from a single crystal
using the beamline 1911-3 at MAX-lab (Lund, Sweden), and
the structure of GLP-1 in complex with the GLP-1R ECDwas
solved to 2.1 Å resolution by molecular replacement (Fig.
1A). We removed exendin-4(9–39) from the structure of the
exendin-4(9–39)-ECD complex (Protein Data Bank code
3C59) and used the apo-form of GLP-1R ECD as the search
model for the molecular replacement. GLP-1 was then built
into themodel; its position was unambiguous due to good elec-
tron density for most of the ligand. Data collection and refine-
ment statistics are summarized inTable 1. Throughout the text,
GLP-1 and exendin-4 residues are designated with * and **,
respectively. Exendin-4 is numbered 1–39 and GLP-1 is num-
bered 7–37, due to post-translational processing. The aligned
sequences are illustrated in Fig. 1B.
FIGURE 1. Structure of the GLP-1-bound ECD of the GLP-1R. A, stereoview of GLP-1 (blue) bound to the ECD
of theGLP-1R (-helix in black,-strands in red, and loops in gray). Disulfide bridges are shown as orange sticks.
Residues Cys62–Asp67 (1) and Ala
70–Gly75 (2) constitute the first region of antiparallel -sheets, and the
second region is comprised of residues Gly78–Ser84 (3) and His
99–Thr105 (4), which is shown in red. Our final
structure contains GLP-1 residues Gly10*–Gly35*. The residues that interact with GLP-1R ECD lie within Ala24*
and Val33*, which are shown as sticks. B, sequence alignment of GLP-1, exendin-4, GIP, GLP-2, glucagon, and
PACAP(1–27). Fully conserved residues are highlighted in yellow, and partially conserved residues are high-
lighted in green. The residues of GLP-1 and exendin-4 that interact with GLP-1R ECD are colored blue. The
underlined residues symbolize residues of GLP-1 in -helical conformation when bound to the ECD. Residue
number 1 of exendin-4 corresponds to residue number 7 of GLP-1.
Crystal Structure of Receptor-bound GLP-1
JANUARY 1, 2010•VOLUME 285•NUMBER 1 JOURNAL OF BIOLOGICAL CHEMISTRY 725
 at D
EF Consortium
 - Tech K
now
ledge Ctr of D
enm
ark on D
ecem
ber 15, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Structure of the GLP-1R Extracellular Domain—The crystal
structure of the ECD in the GLP-1-bound form shown here is
very similar to the exendin-4(9–39)-bound form shown previ-
ously (root mean square deviation of 0.79 Å for C atoms of the
ECD) (18). The ligand-binding sites are identical, which is not
surprising given the competitive binding of GLP-1 and
exendin-4 for the full-length GLP-1R as well as the isolated
ECD (27). However, we have previously shown that divergent
residues in the two ligands are responsible for their different
physical properties in solution and their different affinity for
the ECD (27). As described below, these divergent residues give
rise to structural differences in the two ligand-bound forms of
the ECD at the level of specific side chain conformations.
Structure of GLP-1 and Its Interactions with the Extracellular
Domain of GLP-1R—GLP-1 is a continuous -helix from
Thr13* to Val33*, with a kink around Gly22*. The residues
between Ala24* and Val33* interact with the ECD (Fig. 1, A and
B). The amphiphilic nature of this -helical segment enables
hydrophilic and hydrophobic interactions through opposite
faces of the -helix. The hydrophilic face is comprised by resi-
dues Gln23*, Lys26*, Glu27*, and Lys34*. Lys26* is the only one of
these thatmay interact directlywith the ECD (Fig. 2A). The side
chain of Lys26*may formahydrogen bondwith the side chain of
Glu128 (3.0Å), but theB-factor is rather high for both residues
(25 compared with 10 for well defined residues), suggesting
that this is not a strong interaction. In particular, the electron
density of the Lys26* side chain is rather weak. In exendin-4(9–
39), the amphiphilic character is more pronounced, and the
-helical conformation is further stabilized by intramolecular
interactions between Glu16**, Glu17**, Arg20**, Glu24**, and
Lys27** on the hydrophilic face (18). In addition, Arg20** and
Lys27** interact withGlu128 andGlu127 of the ECD, respectively
(18). The corresponding intramolecular stabilization is not pos-
sible in GLP-1 due to a less favorable alignment of oppositely
charged residues (Fig. 1B), and Glu127 of the ECD is not
involved in binding of GLP-1 (Fig. 2A).
The hydrophobic face of GLP-1, which interacts with the
ECD, is defined by Ala24*, Ala25*, Phe28*, Ile29*, Leu32*, and
Val33* (Fig. 2B). The importance of Phe28*, Ile29*, and Leu32* in
GLP-1 binding has been demonstrated previously by Ala scan-
ning of GLP-1 (38). Substitution of Phe28* with Ala had the
most severe effect on GLP-1 affinity in the Ala scan (IC50 value
increased by 1300-fold), and indeed Phe28* is centrally posi-
tioned in the ligand-receptor interface emphasizing the impor-
tance of this hydrophobic ligand-receptor interaction. The
I29*A and L32*A substitutions also reduced GLP-1 affinity sig-
nificantly (IC50 value increased by 93- and 17-fold, respectively)
(38). Trp31* is also on the hydrophobic face of GLP-1 but is
rather solvent-exposed and does not interact with the ECD
(Fig. 2B). Trp31* is conserved in the
glucagon peptide family (GLP-1,
exendin-4, glucagon, GIP, and
GLP-2, see Fig. 1B), which implies a
unique role of this residue. How-
ever, substitution of Trp31* with Ala
only reduced the binding affinity of
GLP-1 slightly at the full-length
GLP-1R (38), so the role of Trp31* in
receptor binding is unclear.
Val33* is the final residue in the
-helix of GLP-1, and it is the final
residue in the C terminus of GLP-1
that interacts with the ECD (Fig. 2,
A and C). The side chain of Val33*
makes hydrophobic contacts with
Tyr69 and Leu123, and the backbone
carbonyl of Val33* interacts through
a hydrogen bondwith one of the ter-
minal nitrogens of Arg121 (Fig. 2, A
andC). The other terminal nitrogen
ofArg121 interactswith awatermol-
FIGURE 2. Interactions between GLP-1 and GLP-1R ECD. A, ribbon diagram of GLP-1 and its hydrophilic
interactionswithGLP-1RECD.GLP-1 is colored in cyan, and residuesGln23*, Lys26*, Glu27*, Trp31*, andVal33* are
illustrated as sticks. Receptor residues Arg121, Leu123, Glu127, and Glu128 are shown as sticks. The surface of the
hydrophilic binding cavity of ECD is illustrated in gray. B, ribbon diagram of GLP-1 and its hydrophobic inter-
actions with GLP-1R ECD. GLP-1 residues Ala24*, Glu27*, Phe28*, Trp31*, and Leu32* are illustrated as sticks, and
so are ECD residues Leu32, Trp39, Asp67, and Arg121. The surface of the hydrophobic binding cavity of ECD is
illustrated in gray. C, ribbon diagram illustrating a common motif found in the GLP-1R ECD and in the GIP
receptor ECD. The side chain of Arg121 interacts with the backbone carbonyls of Asp67 and Leu32* through a
water molecule. GLP-1 residues Leu32* and Val33* are illustrated as sticks, and so are ECD residues Asp67 and
Arg121.
TABLE 1
Data collection and refinement statistics
The data set was collected from a single crystal. Values in parentheses are for the
highest resolution shell (2.2-2.1 Å).
Space group P21221
Unit cell dimensions (Å)
A 35.7
B 42.7
C 95.1
Data collection
Wavelength 1.0 Å
Resolution range 95.1–2.1 Å (2.2–2.1 Å)
Total reflections 73,811
Unique reflections 10,348
Completeness 97.9%
I/(I) 14.0 (5.3)
Rsym 11.1 (44.9)
Refinement statistics
No. of non-hydrogen atoms 1109
Resolution 95.1-2.1 Å (2.155-2.100 Å)
Total reflections 8786
Reflections in test set 429
Rwork 0.181 (0.187)
Rfree 0.226 (0.255)
Average B-factors 13.6
Root mean square deviation
Bond lengths 0.02 Å
Bond angles 1.7°
Crystal Structure of Receptor-bound GLP-1
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ecule, which is also coordinated by the backbone carbonyl
groups of Asp67 and Leu32* (Fig. 2C). A water molecule is coor-
dinated by the same residues in the exendin-4(9–39)-bound
ECD, and Arg121 interacts with the backbone carbonyl of
Lys27** of exendin-4(9–39) in a manner similar to the interac-
tion with Val33* of GLP-1. Even though exendin-4 has a C-ter-
minal nine-residue extension, the so-calledTrp cage, the extent
of the -helix is similar for GLP-1 and exendin-4, and this par-
ticular length of the -helix fits nicely into the ECD binding
pocket.
Judging from the two ligand-bound ECD structures, the
hydrophobic ligand-receptor interface is highly conserved, and
the C-terminal -helical structure of the ligands ends at the
same position with a similar arrangement of receptor interac-
tions mediated by the backbone of the ligand. Hence, the dif-
ferential affinity for the ECDmay best be explained by the lower
-helical propensity of GLP-1 in solution and by weaker recep-
tor interactions compared with exendin-4, as suggested previ-
ously (27).
Unique Structural Features of the GLP-1-bound Extracellu-
lar Domain—The divergent residues in GLP-1 and exendin-4
are not only responsible for the different physical properties
of the ligands in solution and their differential affinity for the
GLP-1R ECD, they also influence the conformation of certain
residues in the ECD structures. The crystal structure presented
here suggests that one diverging residue in the two ligands
(Val33* of GLP-1 and Lys27** of exendin-4(9–39)) causes a shift
in the conformations of four residues in (or close to) the binding
pocket of the ECD, namely Glu127, Leu123, Arg121, and Pro119
(Fig. 3A). In exendin-4(9–39), Lys27** interacts with Glu127,
and the positioning of the Lys27** side chain appears to be
guided by a hydrophobic interaction with Leu123. In GLP-1,
Val33* is unable to interact with Glu127 causing Glu127 to
change rotamer conformation and point its side chain away
from GLP-1. The side chain of Leu123 is flipped toward Arg121,
which again is flipped toward
Pro119, thereby closing an otherwise
water-accessible cavity observed in
the exendin-4(9–39)-bound struc-
ture (Fig. 3A). The closing of this
cavity is assisted by a side chain flip
of Pro119 toward Arg121. The appar-
ent GLP-1-specific conformations
affect the conserved core of the ECD
by rotating the guanidine group of
Arg102 and by decreasing the dis-
tance between Asp67 and Arg102
compared with the exendin-4(9–
39)-bound structure without affect-
ing the relative position and confor-
mation of Trp72 and Trp110 (Fig.
3B). This enables a direct interac-
tion through a hydrogen bond
between Asp67 and Arg102 unlike
what we observed in the exendin-
4(9–39)-bound structure, where a
water molecule mediated the inter-
action between Asp67 and Arg102
(Fig. 3B). The functional consequences of the ligand-specific
conformational differences are not known.
Site-directed Mutagenesis of the GLP-1R—To link the struc-
tural information of the isolated ECD with the binding and
functional properties of the full-length receptor, we targeted
the ligand-binding site of the ECD by site-directed mutagene-
sis. The mutants were characterized by their ability to bind
GLP-1 and exendin-4, using the agonist 125I-GLP-1 tracer, and
by their ability to stimulate cAMP production in response to
GLP-1 and exendin-4 (Table 2). The main objective was to
search for mutations with differential effect on GLP-1 and
exendin-4. We initially focused on Glu127, which showed an
obvious conformational difference in the two ligand-bound
structures (Fig. 3A), Glu127 interacts directly with exendin-
4(9–39) but not with GLP-1 (18). The ECD structures suggest
that the hydrogen-bonding potential of Glu127 is important for
exendin-4 binding but not for binding of GLP-1, and this is
supported by the site-directed mutagenesis data (Table 2).
Mutation ofGlu127 toAla reduced the affinity for exendin-4 but
not for GLP-1 (6.8- versus 1.7-fold, respectively). Glu128 inter-
acts with a positively charged residue in both GLP-1 and
exendin-4, which may explain why the E128A substitution did
not have a differential effect on the binding affinity of GLP-1
and exendin-4. The differential effect of the E127Amutation on
GLP-1 and exendin-4 binding is rather small compared with
the differential affinity of the isolated ECD shown previously
(27). Clearly, the superior helical propensity of exendin-4 con-
tributes strongly to its high affinity for the ECD.
Several interactions are conserved in the twoECDstructures,
and mutagenesis of the implicated receptor residues was not
expected to have differential effects on ligand binding (Table 2).
Surprisingly, the L32A mutation reduced both the affinity
and potency of exendin-4 relative to GLP-1 (7.1- and 9.5-fold,
respectively, see Table 2 and Fig. 4), demonstrating a ligand-
specific effect of the L32A mutation. Neither the potency nor
FIGURE3.DifferencesbetweentheGLP-1-andexendin-4(9–39)-boundstructureofECD.Ribbondiagrams
showing significant differences in side chain conformations between the GLP-1-bound structure and the
exendin-4(9–39)-bound structure of GLP-1R ECD. Receptor and ligand residues are highlighted in blue for the
GLP-1-bound structure and in orange for the exendin-4(9–39)-bound structure.Watermolecules in orange are
present only in the exendin-4(9–39)-bound structure. A, one diverging residue, Val33* of GLP-1 and Lys27** of
exendin-4(9–39), causes a shift in the conformations of four residues, namelyGlu127, Leu123, Arg121, and Pro119.
B,GLP-1-specific conformations affect the conserved coreof the ECDby rotating theguanidinegroupofArg102
and by decreasing the distance between Asp67 and Arg102 compared with the exendin-4(9–39)-bound struc-
ture without affecting the relative position of Trp72 and Trp110.
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the affinity ofGLP-1was affected by the L32Amutation (Fig. 4),
and the expression level of the receptorwas similar towild-type
GLP-1R, which confirmed the structural integrity of this
receptor mutant. Leu32 is the first
residue in the-helix of theGLP-1R
ECD, and it defines the border of
the hydrophobic binding cavity by
interacting with Ala24*, Ala25*, and
Phe28* (Fig. 2B). The results suggest
that Leu32 is important for the bind-
ing of exendin-4 but not for the
binding of GLP-1 to GLP-1R. It is
difficult to give a structural explana-
tion of the ligand-specific effect of
the L32A mutation by comparing
the two ligand-bound forms of the
ECD, because the structural differ-
ences in this region are quite subtle.
Nevertheless, the ligand-specific
effect of the L32A mutation sup-
ports the existence of differences in
the binding modes of GLP-1 and
exendin-4 to the full-length GLP-1R.
Clearly, the two-domain binding
mechanism of the full-length GLP-
1R is more complex than binding of
the isolated ECD.
Conformation of GLP-1, Recep-
tor-bound and in Solution—GLP-1
is highly flexible in aqueous buffers,
whereas in trifluoroethanol a single-
stranded -helix forms (Thr13* to
Lys34*) with a less defined -helical
region around Gly22*, as demon-
strated by NMR spectroscopy (33,
39). Structure-activity studies of
GLP-1 showed that side chain to
side chain cyclization by lactam
bridge formation of residues 16–20
and 18–22 were well tolerated. Cyclization of residues 11–15
improved potency for GLP-1R compared with the linear coun-
FIGURE4.Functional andbindingproperties of the L32AGLP-1Rmutant.Upper panel, stimulationof cAMP
production by transiently transfected HEK293 cells expressing the L32A mutant by GLP-1 (squares, A) and
exendin-4 (circles, B).Dashed dose-response curves represent cAMP production by GLP-1 and exendin-4 at the
wild-type GLP-1R, respectively. Lower panel, competition binding assay on plasma membranes from tran-
siently transfectedHEK293 cells expressing the L32Amutant. GLP-1 binding curves are presentedwith squares
(C) and exendin-4 curves with circles (D). Dashed binding curves represent 125I-GLP-1 displacement by GLP-1
andexendin-4 at thewild-typeGLP-1R.Data arenormalizedaccording to 125I-GLP-1bindingandcorrespond to
three independent experiments performed in duplicate.
TABLE 2
Functional and binding experiments with GLP-1Rmutants
EC50 and IC50 values are given in pM and nM, respectively, and expression levels are given in fmol/mg total protein. Data represent the mean  S.E. of three or more
independent experiments performed in duplicate. The EC50 or IC50 values of GLP-1 and exendin-4 are compared with the wild-type GLP-1R using the unpaired t test.
Numbers in parentheses equal the relative difference between EC50 or IC50 values of GLP-1 and exendin-4 at eachmutant comparedwith the wild-type receptor. NDmeans
not detectable, possibly due to no expression or no binding. * indicates p 0.05; **, p 0.01; and no asterisk means no significant difference.
Mutant EC50 IC50 Expression levelGLP-1 Exendin-4 GLP-1 Exendin-4
pM nM fmol/mg
Wild type 11 3.2 5.5 1.7 1.0 0.20 0.76 0.19 5.5 0.16
L32A 12 2.7 (1.1) 52 24 (9.5) 1.1 0.17 (1.1) 5.4 1.5* (7.1) 6.0 0.40
T35A 30 7.4 (2.7) 23 12 (4.2) 3.1 0.80 (3.1) 0.44 0.1** (0.6) 0.38 0.01
V36A 57 32 (5.2) 36 20 (6.5) 2.8 0.86 (2.8) 0.98 0.34 (1.3) 5.7 0.28
E68A 15 2.4 (1.4) 9.5 4.2 (1.7) 1.9 0.90 (1.9) 0.48 0.07 (0.6) 5.7 0.07
Y69A ND ND ND ND ND
Y88A ND ND ND ND ND
L89A ND ND ND ND ND
P90A 55 12* (5.0) 30 7.3* (5.5) 2.8 1.6 (2.8) 1.6 0.28 (2.1) 5.6 0.22
R121A 51 13* (4.6) 44 10* (8.0) 2.3 1.1 (2.3) 1.2 0.02 (1.6) 5.7 0.37
L123A 17 4.6 (1.5) 9.5 1.9 (1.7) 1.1 0.38 (1.1) 0.33 0.04 (0.4) 2.6 0.09
E127A 13 4.2 (1.2) 11 0.45* (2.0) 1.7 0.76 (1.7) 5.2 2.0 (6.8) 5.6 0.46
E127Q 12 3.3 (1.1) 6.8 1.4 (1.2) 1.1 0.27 (1.1) 0.82 0.15 (1.1) 6.11 0.21
E128A 28 6.2 (2.5) 25 6.7* (4.5) 2.7 0.91 (2.7) 1.8 0.48 (2.4) 6.0 0.49
E128Q 10 3.0 (0.9) 8.0 3.3 (1.5) 0.66 0.11 (0.7) 0.45 0.1 (0.6) 5.2 0.12
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terpart (40, 41). These data support the existence of an-helical
conformation in the N-terminal part of GLP-1 when bound to
the full-length GLP-1R. It is interesting that in the ECD-bound
structure, the Thr13*–Glu21* segment of GLP-1 adopts an
-helical conformation even though this segment does not
interact with the ECD. The C-terminal segment of GLP-1
(Ala24*–Val33*) is stabilized in a specific-helical conformation
throughbinding to the ECD.Thismay subsequently stabilize an
-helical conformation in the N-terminal part of the ligand
(Thr13*–Glu21*). This hypothesis is supported by the solution
structure of GLP-1 in different concentrations of trifluoroetha-
nol (39). GLP-1 is a random coil in pure water, but adding tri-
fluoroethanol enables the C-terminal segment of GLP-1 to
adopt an-helix conformation. TheC-terminal-helix is grad-
ually extended toward the N-terminus of the peptide with
increasing concentrations of trifluoroethanol (39), and it seems
possible that a similar mechanism is initiated upon binding of
GLP-1 to the ECD. It was recently proposed that -helix for-
mation of the ligand upon binding
to the ECD is an important step in
the activation of class BGPCRs (23).
As shown in Fig. 5A, the -helix
of GLP-1 has a central distortion of
the backbone around Gly22*, which
is not observed in the exendin-4(9–
39)-bound structure. The distortion
is also observed in the NMR struc-
tures of GLP-1 in solution (39).
However, we cannot exclude that
the kink observed in the crystal
structure is a result of crystal pack-
ing between the N-terminal part of
GLP-1 (Gly10*–Glu21*) and symme-
try-related ECDs rather than a func-
tionally important characteristic of
GLP-1 (Fig. 5, B–D). Substitution of
Gly22*withAlawas previously shown
not to affect the functionality or the
binding affinity of GLP-1, which sug-
gests that flexibility around Gly22* is
not required for binding to or acti-
vation of GLP-1R (38). Interest-
ingly, Leu32 of the ECD is positioned
right next to the kink of GLP-1 (Fig.
5A). Thus, we have demonstrated a
ligand-specific effect of the L32A
mutation and have shown that
ECD-bound GLP-1 has a kink right
next to Leu32, whereas ECD-bound
exendin-4(9–39) is straight. This
may be a coincidence, but it is
tempting to speculate that there is a
connection between the structural
difference of the ligands (kinked or
straight helix) and the differential
effect of the L32A mutant on bind-
ing of the ligands.
A three-dimensional model of
GLP-1R was recently published (21). From the NMR structure
of GLP-1 in trifluoroethanol (Protein Data Bank code 1D0R
(39)), it was suggested that GLP-1 might assume one of two
forms when bound to GLP-1R, a slightly kinked -helix or an
L-shaped -helix, and the authors concluded that the L-shaped
-helix conformation of GLP-1 seemed more reasonable
(21). The crystal structure presented here is more compatible
with the kinked conformation of GLP-1.
The structure of His7*–Gly10* was not determined in this
study probably due to the inherent flexibility in this part of
GLP-1 and other peptide ligands for class B receptors (33, 39,
42, 43). The only structural evidence showing a unique confor-
mation comes from a structural study of PACAP(1–21) com-
paring micelle- and receptor-bound states. Residues 1–7 of
PACAP(1–21) adopt a specific -coil structure upon receptor
binding followed by an -helical structure of residues 8–21
(44). The relevance of the receptor-boundPACAP(1–21) struc-
ture for GLP-1 in particular is supported by a previous study of
FIGURE 5. Crystal packing. A, superposition of ECD-bound GLP-1 (blue) and exendin-4(9–39) (cyan). GLP-1
residue Gly22* denotes a kink in the -helix, which is situated in close proximity to Leu32 of the ECD. B, crystal
packing involving symmetry-related complexmolecules. C, ribbon diagram of GLP-1 (blue) and its interactions
with the ligandof a symmetry-relatedmolecule. Residues Tyr19*, Gln23*, andGlu27* are shownas sticks, and the
surface of the GLP-1R ECD is shown in gray. The packing of complex molecules allows Tyr19* to interact with
Gln23* (3 Å) and Glu27* (2.5 Å) in a symmetry-related ligand molecule. D, interactions between GLP-1 and
residues of symmetry-related ECD molecules. GLP-1 residues Thr11*, Thr
13*, Ser14*, and Glu21* are shown as
sticks. The backbone carbonyl of Thr11* could form a weak hydrogen bond (3.2 Å) to the backbone amide of
Gln112, the backbone amide of Thr13* could form a hydrogen bond (2.9 Å) to the backbone carbonyl of Gln112,
and the backbone amide of Ser14* may form a hydrogen bond (3 Å) to the side chain of Asp114. The side chain
of Glu21* forms a hydrogen bond to the backbone amide of Phe80 (2.6 Å).
Crystal Structure of Receptor-bound GLP-1
JANUARY 1, 2010•VOLUME 285•NUMBER 1 JOURNAL OF BIOLOGICAL CHEMISTRY 729
 at D
EF Consortium
 - Tech K
now
ledge Ctr of D
enm
ark on D
ecem
ber 15, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
chimeric PACAP/GLP-1 peptides (45). Substituting five resi-
dues from the N-terminus of GLP-1 with those of PACAP (three
nonconserved, Fig. 1B) had no effect on either the affinity or
potency for GLP-1R. Thus, on the basis of both sequence
homology and structure-activity, GLP-1 would be expected to
adopt a similar conformation upon binding to the GLP-1R TM
domain.
Conclusion—The crystal structure presented here shows
the molecular details of GLP-1 binding to the GLP-1R ECD,
an essential step in the two-domain binding mechanism of
GLP-1R and class B GPCRs in general. Collectively, results
from structural characterization of GLP-1 in solution, struc-
ture-activity analyses ofGLP-1 analogues, and the crystal struc-
ture of GLP-1 bound to the GLP-1R ECD presented here sug-
gest that GLP-1 is a continuous -helix from Thr13* to Val33*
when bound to the full-lengthGLP-1R. This is important infor-
mation for the design of peptide therapeutics targeting GLP-
1R. GLP-1 and exendin-4 share the same binding site of the
GLP-1R ECD, but the ligand-specific effects on the ECD struc-
ture and the ligand-specific effects of receptor mutagenesis
support the existence of differences in the binding modes of
GLP-1 and exendin-4 to the full-length GLP-1R. The nature of
these differences as well as the active conformation of peptide
agonists (kinked or not) and a better understanding of the two-
domain binding mechanism await structural characterization
of the full-length GLP-1R.
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Supplemental Data 
 
 
 
 
 
Figure S1. SDS-PAGE of the purified GLP-1-bound ECD  
The GLP-1-bound ECD was purified by size exclusion chromatography and the eluted complex was 
characterised by SDS-PAGE. Fractions 27-35 from Superdex75 are indicated. The overall molecular 
mass (MW) of the purified complex is 18.3 kDa, where MW of the GLP-1 ECD is 14.7 kDa and MW 
of GLP-1(7-37) is 3.6 kDa. 
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